Servier Pharmaceuticals LLC and Les Laboratoires Servier to acquire Edgewise Therapeutics, Inc.

Servier Pharmaceuticals LLC and Les Laboratoires Servier have agreed to acquire Edgewise Therapeutics, Inc. in a strategic acquisition valued at $2.65 billion. The transaction, which was announced on 1 June 2026, involves a consideration structure comprising both cash and earn-out components. This deal represents a significant move within the healthcare sector, bringing the US-based biotechnology firm under the ownership of the international pharmaceutical group. The headline offer price reflects the strategic value placed on Edgewise’s pipeline and technological assets by the acquiring entities.

The acquisition was completed on 10 July 2026, following the announcement period. Both parties are based in the United States, facilitating a domestic transfer of control within the healthcare industry. The deal structure allowed for a mix of immediate liquidity and future performance-based payments, aligning the interests of the sellers with the long-term potential of the target company. This completion marks the end of the negotiation phase and the beginning of integration for Edgewise Therapeutics into the broader Servier organization. The transaction is now fully executed and closed.